The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
1
1
2
Edited News | UN WOMEN
Sudan: Women’s bodies ‘a crime scene’ as tens of thousands flee El Fasher atrocities – UN Women
In war-torn Sudan rape is being systematically used as a weapon and simply being a woman is ‘a strong predictor’ of facing hunger, violence and death, the UN’s gender equality agency warned on Tuesday.
1
1
1
Edited News | OHCHR
The UN human rights office (OHCHR) on Friday called for an end to continuing expansion of Israeli settlements in the occupied West Bank, where “unchecked” settler violence has surged since the war in Gaza began more than two years ago.
1
1
1
Edited News | WFP
The crisis in eastern Democratic Republic of the Congo (DRC) continues to worsen amid ongoing fighting that has driven tens of thousands of people from their homes and created acute hunger, the UN World Food Programme (WFP) said on Friday.
1
1
1
Edited News | WFP
Gaza: One million receive food parcels as humanitarians race to ‘push back hunger’
Food is slowly returning to the shelves in Gaza amid “apocalyptic scenes” but supplies are still desperately inadequate, UN humanitarians said on Tuesday, as they issued fresh calls for wider access and continued financial support.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Office spokesperson Seif Magango today told the bi-weekly UN press briefing in Geneva of more details that are emerging on the atrocities committed in El Fasher, in Sudan during and after its takeover by the Rapid Support Forces.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Office spokesperson Seif Magango made the following comment on Friday at the bi-weekly press briefing in Geneva.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Office spokesperson Ravina Shamdasani made the following comment on Friday at the bi-weekly press briefing in Geneva.
1
1
1
Edited News | OHCHR , WHO
Sudan: UN Raises Alarm Over Mass Atrocities in El Fasher as Survivors Report Executions, Killings and Rapes
More details continue to emerge about atrocities committed during and after the fall of El Fasher to the Rapid Support Forces (RSF) in Sudan on 23 October. Since the powerful paramilitary group made a major incursion into the city last week, the UN Human Rights Office has received “horrendous accounts of summary executions, mass killings, rapes, attacks against humanitarian workers, looting, abductions and forced displacement,” said Seif Magango, spokesperson for the Office of the United Nations High Commissioner for Human Rights (OHCHR).
1
1
1
Edited News | OCHA
Ukraine: Russian attacks on energy terrorize population as winter starts; could trigger major ‘crisis within crisis’
The UN’s top aid official in Ukraine expressed concern on Friday about “continuous attacks” on energy production sites and distribution facilities.
1
1
1
Edited News | HRC
Navi Pillay Retires After Decades Defending Human Rights and Pursuing Justice
1
1
1
Edited News | OHCHR , UNOG
The telecommunications shutdowns in Afghanistan in September had serious and far-reaching impacts on people’s lives, according to a briefing paper published today by the UN Human Rights Office and the UN Assistance Mission in Afghanistan (UNAMA).
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Office spokesperson Jeremy Laurence at the UN Geneva press briefing made the following comment on the ASEAN declaration on the right to a healthy environment.